Quality of life in hypothyroid subjects treated with levothyroxine: a cross-sectional study Authors: Hamide Rezaeizade, Motahare Shabestari, Narjes Hazar, Akram Ghadiri-Anari, Marjan Mehrali, Mohammad Salehi-Shadkami, Reyhaneh Azizi Published: 2026 ABSTRACT ObjectivesHypothyroidism is a disorder characterized by insufficient thyroid hormone production; its manifestations can lead to impaired function and health-related quality of life. This study is aimed to compare the quality of life (QoL) in levothyroxine(LT4)-treated patients with serum thyroid hormone levels equivalent to those of healthy controls.Materials and methodsThis cross-sectional investigation enrolled 220 participants, including 110 hypothyroid individuals treated with LT4 as the case group and 110 euthyroid subjects as the controls. Demographic variables (age, sex, marital status, occupation, and education), QoL, and mean thyroid function indices (Thyroid Stimulating Hormone, Triiodothyronine, and Thyroxine) were assessed and compared between the two groups. The QoL was evaluated using the World Health Organization Quality Of Life (WHOQOL) -BREF Questionnaire.ResultsOur findings demonstrated that QoL scores across the subscales of physical health, mental health, social relationship, environment, and overall QoL and general health were significantly lower in the LT4-treated (case) group compared to the healthy (control) group (p < 0.001). Multiple linear regression showed that disease status (B=-18.61, p < 0.001), education level (B = 4.42, p = 0.005), and mean Triiodothyronine (T3)(B = 0.41, p < 0.001) are independent predictors for QoL.ConclusionsPatients on LT4 therapy have a significantly lower QoL despite achieving serum thyroid hormone levels equivalent to those of healthy controls. Introduction Hypothyroidism is a prevalent clinical syndrome that occurs due to a decreased production of thyroid hormones or impaired hormone activity. The condition is among the most pervasive endocrine disorders, with a reported prevalence of 3.6–5.1% in adults [1]. Thyroid hormones, including thyroxine (T4) and triiodothyronine (T3), contribute to modulating various physiological processes through the regulation of gene transcription. However, T4 is not the active biological form and needs to be converted to T3 in peripheral tissues by iodothyronine deiodinase enzymes, which exhibits a high affinity for binding to the receptors and exerts biological effects [2]. Thyroid hormone insufficiency causes a decrease in metabolism, resulting in clinical manifestations such as fatigue, xeroderma, menstrual irregularity, constipation, edema and facial puffiness. Additionally, thyroid gland functions have essential effects on cerebral metabolism and homeostasis, such that hypothyroidism contributes to cognitive impairment, mood disorders, depression, and psychosis [1]. Hypothyroidism substantially impairs patients’ multiple aspects of life including fertility, resulting in diminished quality of life (QoL) and overall health [3, 4]. Synthetic levothyroxine (LT4) has been used as a lifelong medication for patients since the 1970s with the aim of maintaining serum TSH levels within the reference range [3]. While this treatment has improved patients’ QoL, it has not been able to fully normalize the QoL to levels observed in the population without thyroid disorders [3]. As many patients remained unsatisfied with LT4 monotherapy, previous studies investigated the efficacy of combined LT4 and liothyronine (LT3) therapy, but no significant improvement in the QoL was reported [1, 5]. It is noteworthy that combination therapy with LT4/LT3 may lead to greater suppression of TSH levels, a phenomenon that prior studies have correlated with cognitive impairment and increased long-term risks, including higher mortality [6] and a greater likelihood of developing dementia [7]. In the management of chronic disease, improving patients’ QoL is just as important as treating the underlying condition. In hypothyroidism, the optimal treatment strategy and appropriate measures of therapeutic success remain debated. This study assessed whether LT4 improves quality of life (QoL) in treated hypothyroid patients who have normal thyroid function tests. We compared this patient group to a healthy control population with no history of thyroid disease. Materials and methods Study protocol and participants This observational, cross-sectional study was conducted in 2017 and 2018 at the outpatient endocrinology clinic of Shahid Sadoughi University of Medical Sciences, Iran. A total of 220 euthyroid participants were enrolled, comprising 110 individuals receiving LT4 therapy (case group) and 110 healthy subjects (control group). The inclusion criteria for the case group were regular use of LT4 for at least six months and serum thyroid-stimulating hormone (TSH) levels within the reference range (0.5-4.5mIU/ml). The exclusion criteria of the case group included any recent changes in LT4 dose and the presence of any mental, neurological, hematologic, oncological, infectious, renal, rheumatological or critical care-related conditions. None of our studied group had undergone thyroidectomy or had dyshormonogenetic goiter or Hashimoto’s disease with huge goiter. Control group participants had normal thyroid function tests and no history of thyroid disease, mental illness or other incurable diseases. All the subjects were aged over 18 years old and were on LT4 monotherapy only with 75–150 mcg LT4 daily. Cases and controls were matched for age and sex during recruitment to ensure comparability between groups. Participants filled study questionnaire in paper form in clinic. A researcher helped subjects completing forms upon request or in capability. Ethical considerations The present study protocol followed the principles of the Declaration of Helsinki and was also approved by the Ethics Committee of Shahid Sadoughi University of Medical Sciences, Yazd, Iran (Code: IR.SSU.MEDICINE.REC.1399.044). The study’s objectives were explained to all participants, and written informed consent was obtained from them. WHOQOL-BREF questionnaire Quality of life was assessed using the validated Farsi version of the World Health Organization Quality of Life (WHOQOL)-BREF questionnaire. The questionnaire consists of 26 questions and covers four domains: physical health, psychological health, social relationships, and environment [8]. The Farsi WHOQOL-BREF has been validated and shown to be reliable by Nejat et al. The reliability scores of the mentioned domains were obtained at 0.77, 0.77, 0.55, and 0.84, respectively [9]. All items in the WHOQOL-BREF questionnaire were rated on a five-point Likert scale (1 = not at all, 5 = very much). For negatively worded items (questions 3, 4, and 26), scores were reversed so that higher values consistently reflected better quality of life. Domain scores were calculated by summing the relevant items, yielding raw values that could range from 4 to 26. To facilitate comparison across domains, raw scores were subsequently transformed to a standardized 0–100 scale, with higher scores indicating better quality of life. Data collection Eligibility was determined by a research team member, and written informed consent was obtained from all participants. During individual interviews, participants were instructed on how to complete the WHOQOL-BREF questionnaire. Demographic variables (age, gender, marital status, occupation, and education level) and laboratory data (serum T3, T4, and TSH levels), were obtained from medical records. Serum T3, T4, and TSH level was measured using Pishgaman (Iran, Tehran) ELISA assay kit. Sample size The minimum required sample size for this study was estimated as 214 participants, with 107 individuals in each group. This estimation was based on previously reported mean QoL scores of 72.29 ± 10.16 in the treated euthyroid group and 68.38 ± 10.68 in the healthy group. A two-sided significance level of 95%, and a statistical power of 80% was applied, based on Rakhshan et al. [10]. The sample size was calculated using the following formula:\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$n = \frac{{{{\left({_{Z1-\frac{\alpha}{2} + Z1 - \beta}} \right)}^2}\left( {\sigma _1^2 + \sigma _2^2} \right)}}{{{{\left( {{\mu _1} - {\mu _2}} \right)}^2}}}$$\end{document} Statistical analysis All statistical analyses were conducted using the Statistical Package for the Social Sciences software (SPSS, version 27.0 for Windows; IBM Corp., Chicago, IL, USA). Group differences in continuous and categorical variables were compared using independent sample t-tests and Chi-square tests, respectively. Continuous data are presented as mean ± standard deviation (SD), and categorical data as frequencies and percentages. To explore the predictors of QoL scores, multiple linear regression was performed, incorporating disease status (case vs. control), occupation (employee vs. other), education level (academic vs. diploma or lower), marital status (married vs. other), and serum concentrations of T3, T4, and TSH. A p-value < 0.05 was considered statistically significant. Results Data from 110 LT4-treated hypothyroid patients (case group) and 110 euthyroid individuals (control group) were analyzed. The mean age of participants was 36.98 ± 7.91 years; 38.2% were men and 61.8% were women. The case and control group were similar in terms of age and sex, according to the matching applied during study design. Baseline characteristics, including marital status, educational level, occupation, and serum levels of TSH, T3, T4, and T4/T3 ratio did not differ significantly between groups (p > 0.001 for each comparison) (Table 1). Participants in the control group demonstrated significantly higher QoL scores in all domains relative to those treated with LT4 (Table 2). Specifically, mean scores for physical health, mental health, social relationships, environment, and overall QoL/general health were all lower in levothyroxine-treated patients (p < 0.001 for each comparison). In multivariable linear regression analysis, medication-derived euthyroidism significantly predicted poorer scores in physical health (B = − 22.3, p < 0.001), mental health (B = − 22.9, p < 0.001), social relationships (B = − 20.1, p < 0.001), environment (B = − 17.2, p < 0.001), and overall QoL/general health (B = − 18.6, p < 0.001), compared with euthyroidism without medication (Table 3). Educational attainment was proved to be a predictor of QoL outcomes. Participants with academic education scored higher in physical health (B = + 4.7, p < 0.001), mental health (B = + 4.8, p < 0.001), social relationships (B = + 3.1, p = 0.028), environment (B = + 2.6, p = 0.004), and overall QoL/general health (B = + 4.4, p = 0.005) (Table 3). Serum thyroid hormone levels were also a predictor of QoL measures. Each unit increase in T3 was linked to higher scores in physical health (B = + 0.46, p < 0.001), mental health (B = + 0.45, p < 0.001), social relationships (B = + 0.42, p < 0.001), environment (B = + 0.30, p < 0.001), and overall QoL/general health (B = + 0.41, p < 0.001). Similarly, T4 predicted improvement in the environment domain (B = + 1.13, p = 0.01), but did not predict changes in other domains (p > 0.001 for each comparison) (Table 3). Serum T4/T3 ratio was also a predictor of QoL measures. Each unit increase in this ratio was linked to higher scores in physical health (B = + 22.7, p < 0.001), mental health (B = + 4.7, p < 0.001), social relationships (B = + 3.7, p < 0.001), environment (B = + 3.3, p < 0.001), and overall QoL/general health (B = + 4.2, p < 0.001) (Table 3). Table 1Demographic characteristics of study participants in two groupsVariablesCase group (N = 110)Control group (N = 110)P- valueMarital Status*Unmarried25 (22.7)35 (31.8)0.116*Married72 (65.5)69 (62.7)Other13 (11.8)6 (5.5)Education*Illiterate5 (4.5)5 (4.5)0.776*Diploma and below42 (38.2)35 (31.8)BSc/BA49 (44.5)56 (50.9)MSc/MA and above14 (12.7)14 (12.7)Occupation*Self-employed35 (31.8)38 (34.5)0.90*Employee36 (32.7)38 (34.5)Unemployed9 (8.2)7 (6.4)Housewife30 (27.3)27 (24.5)Serum TSH level**2.72 (± 0.9)2.70 (± 0.9)0.78**Serum T3 level**117.47 (± 22.8)123.74 (± 21.6)0.92**Serum T4 level**9.36 (± 0.1)9.37 (± 0.1)0.941**T4/T3 Ratio**0.088 (± 0.07)0.077 (± 0.01)0.166***Data presented as N (%), Chi-square test**Data presented as mean ± SD, Student’s t-testTSH: thyroid stimulating hormone; T3: Triiodothyronine, T4: Thyroxine Table 1Demographic characteristics of study participants in two groupsVariablesCase group (N = 110)Control group (N = 110)P- valueMarital Status*Unmarried25 (22.7)35 (31.8)0.116*Married72 (65.5)69 (62.7)Other13 (11.8)6 (5.5)Education*Illiterate5 (4.5)5 (4.5)0.776*Diploma and below42 (38.2)35 (31.8)BSc/BA49 (44.5)56 (50.9)MSc/MA and above14 (12.7)14 (12.7)Occupation*Self-employed35 (31.8)38 (34.5)0.90*Employee36 (32.7)38 (34.5)Unemployed9 (8.2)7 (6.4)Housewife30 (27.3)27 (24.5)Serum TSH level**2.72 (± 0.9)2.70 (± 0.9)0.78**Serum T3 level**117.47 (± 22.8)123.74 (± 21.6)0.92**Serum T4 level**9.36 (± 0.1)9.37 (± 0.1)0.941**T4/T3 Ratio**0.088 (± 0.07)0.077 (± 0.01)0.166***Data presented as N (%), Chi-square test**Data presented as mean ± SD, Student’s t-testTSH: thyroid stimulating hormone; T3: Triiodothyronine, T4: Thyroxine Demographic characteristics of study participants in two groups *Data presented as N (%), Chi-square test **Data presented as mean ± SD, Student’s t-test TSH: thyroid stimulating hormone; T3: Triiodothyronine, T4: Thyroxine Table 2Standardized quality of life scores in study groupsVariablesCase groupControl groupP- value*Physical health score48.6 (± 14.6)74.1(± 11.7)< 0.001Mental health score45 (± 14.4)71 (± 11.3)< 0.001Social relationships score45.8 (± 13.7)68.7 (± 13.2)< 0.001Environment score51.5 (± 9.8)70.7 (± 9.1)< 0.001Overall quality of life and general health score56.7 (± 17)78.1 (± 11.1)< 0.001Data presented as mean ± SD, *Student’s t-test Table 2Standardized quality of life scores in study groupsVariablesCase groupControl groupP- value*Physical health score48.6 (± 14.6)74.1(± 11.7)< 0.001Mental health score45 (± 14.4)71 (± 11.3)< 0.001Social relationships score45.8 (± 13.7)68.7 (± 13.2)< 0.001Environment score51.5 (± 9.8)70.7 (± 9.1)< 0.001Overall quality of life and general health score56.7 (± 17)78.1 (± 11.1)< 0.001Data presented as mean ± SD, *Student’s t-test Standardized quality of life scores in study groups Data presented as mean ± SD, *Student’s t-test Table 3Summary of multiple linear regression modeling for predictors of quality of life scoresDisease Status*Education**Occupation***T3T4T4/T3B P B P B P B P B P B P Physical Health-22.31< 0.0014.67< 0.0011.350.2520.46< 0.0010.870.12122.78< 0.001Mental Health-22.9< 0.0014.79< 0.0011.950.1030.45< 0.0010.740.1954.77< 0.001Social Relationship-20.06< 0.0013.090.028-0.320.8240.42< 0.0010.180.7863.7< 0.001Environment-17.2< 0.0012.570.004-1.280.1610.3< 0.0011.130.013.36< 0.001Total QoL Score-18.61< 0.0014.420.0052.970.0680.41< 0.0011.280.0994.42< 0.001* “control group” as the reference** “high school graduate and lower” as the reference*** “employee” as the referenceB, Unstandardized coefficient (Beta) Table 3Summary of multiple linear regression modeling for predictors of quality of life scoresDisease Status*Education**Occupation***T3T4T4/T3B P B P B P B P B P B P Physical Health-22.31< 0.0014.67< 0.0011.350.2520.46< 0.0010.870.12122.78< 0.001Mental Health-22.9< 0.0014.79< 0.0011.950.1030.45< 0.0010.740.1954.77< 0.001Social Relationship-20.06< 0.0013.090.028-0.320.8240.42< 0.0010.180.7863.7< 0.001Environment-17.2< 0.0012.570.004-1.280.1610.3< 0.0011.130.013.36< 0.001Total QoL Score-18.61< 0.0014.420.0052.970.0680.41< 0.0011.280.0994.42< 0.001* “control group” as the reference** “high school graduate and lower” as the reference*** “employee” as the referenceB, Unstandardized coefficient (Beta) Summary of multiple linear regression modeling for predictors of quality of life scores * “control group” as the reference ** “high school graduate and lower” as the reference *** “employee” as the reference B, Unstandardized coefficient (Beta) Discussion The present study demonstrated that euthyroid patients treated with LT4 for at least six months reported significantly lower QoL across all dimensions -particularly mental and physical components- compared to the healthy control group, as assessed by the WHOQOL-BREF. Importantly, patients in the case group had no chronic comorbidities affecting QoL, and their thyroid function tests (TSH, T4, and T3) were within the reference range. Furthermore, sociodemographic variables—including marital status, educational attainment, and occupational status—were comparable between groups. Thus, the observed differences in QoL cannot be explained by these potential confounders, underscoring the independent association between LT4 treatment and reduced QoL. The results of our study indicate that achieving normal serum thyroid hormone levels with LT4 therapy can improve QoL in patients with overt hypothyroidism but that it remains below that of the general population [11–15]. Rakhshan et al. [10] found that general quality of life in healthy people are significantly better than matched hypothyroidism patients. We wished to more specify that levothyroxine usage in hypothyroidism patients may improve general quality of life. Consistent with our findings, Romero-Gómez et al. investigated a female population of similar mean age and likewise reported reduced mental and physical health among hypothyroid women treated with LT4 [11]. Similarly, Tabakoglu et al. noted that normalization of thyroid hormone levels in patients with Hashimoto’s thyroiditis did not effectively restore QoL [12], reinforcing the notion that serum thyroid hormone levels equivalent to those of healthy control may be insufficient on its own to normalize patient-reported outcomes. In contrast, Molewijk et al. attributed diminished QoL in LT4-treated patients specifically to lower serum T3 concentrations [16]. Our findings challenge this explanation, as serum T3 levels in our case group were similar to those of controls, yet QoL remained impaired. Additional evidence from thyroid-related conditions supports our observation that achieving serum thyroid hormone levels equivalent to healthy controls does not necessarily restore well-being. In a cross-sectional study of 292 papillary thyroid carcinoma (PTC) survivors, Maki et al. found that “the CFS score was significantly correlated with the free T3 level” and that fatigue strongly predicted poorer SF-36 outcomes, noting that “the CFS score was a significant predictor of summary scores of the SF-36.” These results parallel our findings; however, their population consisted of postoperative PTC survivors, whereas participants in our study had no history of thyroid cancer or any thyroid-related malignancy, eliminating cancer-related fatigue as a potential contributor. Moreover, unlike Maki et al., our study did not measure free T3, which may partly explain why we did not observe a similar hormone–symptom relationship. Together, both studies suggest that relying solely on TSH normalization may overlook subtle deficits in T3 availability or tissue-level thyroid hormone action that contribute to persistent symptoms. Although combined LT4/LT3 therapy has been explored as a potential solution, most randomized trials and meta-analyses have not demonstrated consistent improvements in QoL [14, 15, 17–20]. For example, Appelhof et al. reported that combination therapy in two different LT4/LT3 ratios did not significantly outperform LT4 monotherapy in primary hypothyroidism [14]. More recently, a crossover study reported QoL benefits with LT3 monotherapy, but these findings remain isolated and have not influenced current guidelines [21]. Overall, the literature agrees that LT4 therapy alone does not fully restore QoL, though opinions differ on the mechanisms involved and the therapeutic strategies that might address them. Our findings demonstrated that increased serum T4 was associated with physical health improvements, whereas increased T3 was associated with improvements across all domains of QoL, as assessed by the WHOQOL-BREF. The active thyroid hormone in the brain tissue is T3, which is produced locally from T4 by the deiodination function of type 2 deiodinase (DIO2), and serum T3 levels do not play a significant role in providing the brain’s cells’ needs [22]. In hypothyroid rats, LT4 monotherapy was shown to downregulate DIO2, reducing the conversion of T4 to T3 and resulting in inadequate brain T3 levels. This deficit was corrected when LT4 was combined with LT3 [23]. However, the results of the mentioned studies indicated that this kind of treatment was not effective in addressing brain tissue hypothyroidism in humans. One of the potential reasons why a subset of euthyroid LT4-treated patients does not reach the same QoL as the healthy control group could be the polymorphism of the DIO2 gene. Research in this area has been limited and has yielded inconsistent results; while Panicker et al. reported an association between the rs225014 genotype of the DIO2 gene and impaired QoL [24], Wouters et al. did not observe a similar relationship [25]. Additionally, Thr92Ala polymorphism can have a significant impact on QoL by changing the DIO2 enzyme activity. Panicker et al. reported that polymorphism negatively affected QoL [24], whereas Shakir et al. in the Netherlands found no such association [26]. In the present study, TSH levels did not differ significantly between the two groups, suggesting they do not account for the variations in QoL. Notably, TSH levels have been introduced as one of the factors influencing the QoL in patients undergoing treatment for hypothyroidism. Some studies concluded that, unlike normal TSH levels, TSH > 4 mU/L or TSH < 0.40 mU/L were associated with worse QoL [27, 28]. This is inconsistent with the findings of the study by Moron-Diaz et al., which reported that between treated patients with primary hypothyroidism reaching the reference range of TSH, better QOL was correlated with lower TSH levels [29]. More investigations are needed to clarify the impact of subtle variations of TSH on QoL. Loading of autoantibodies against thyroid antigens in Hashimoto’s thyroiditis (HT) was reported to play a role in decreased QoL, even in treated patients [30, 31]. HT is the most common cause of autoimmunity and primary hypothyroidism, characterized by high levels of anti-thyroid peroxidase (anti-TPO) and anti-thyroglobulin (anti-Tg) antibodies [32]. In the context of chronic disease, patients’ general well-being is often impaired [33]. Furthermore, the presence of autoantibodies has been associated with mood disorders [34]. Prior studies have reported that elevated anti-TPO levels are associated with greater symptoms exacerbation and reduced QoL in euthyroid patients with HT [12, 30, 35]. HT reflects alterations in the immune system and is frequently associated with other autoimmune conditions [36], which may further contribute to impaired QoL. Awareness of thyroid disorder and the expectation of LT4 therapy may influence QoL in patients receiving treatment. Several studies have indicated that individuals unaware of their abnormal TSH levels report fatigue and overall health comparable to those without a history of thyroid disease [37–40]. However, a study of 6000 participants revealed that awareness of thyroid disorder, despite reference-range TSH levels, was associated with an increase in self-reported fatigue from 34% to 50% [40]. These findings highlight that how patients perceive their illness and what they expect from treatment can shape their reported quality of life, regardless of their actual thyroid hormone levels. The present study found that subjects’ occupational status does not significantly affect any domains of QoL, while academic education enhances both physical and mental health, especially the former. The strength of the present study lies in excluding people with chronic diseases to avoid their confounding effects on QoL. We also consider subjects’ sociodemographic information, such as marital and occupational status, in our analysis. These results indicate a critical public health issue in Iran, where hypothyroidism is common, and the treatment objectives might need to move beyond normalizing thyroid hormones to include patient-reported outcomes. This study has several limitations to be acknowledged. We did not assess the etiology of primary hypothyroidism or antibody status (anti-TPO, anti-TG), which restricted evaluation of autoimmune contributions to QoL. The cross-sectional design and modest sample size limit causal inference and generalizability, and reliance on self-reported QoL introduces potential bias. Future studies should use larger, longitudinal cohorts with detailed immunological profiling to clarify the association between thyroid autoimmunity and patient-reported outcomes.